Multiple Myeloma

In this fourth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, explains the optimal use of CAR T-cell therapy and common symptoms of adverse effects, including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in relapsed/refractory multiple myeloma.

Andrzej Jakubowiak, MD, PhD, discusses initial efficacy results from the phase 3 ATLAS trial in multiple myeloma.

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Shaji Kumar, MD, discusses the MAIA trial; key takeaways regarding the long-term safety and efficacy of daratumumab, lenalidomide, and dexamethasone, in transplant-ineligible patients with newly diagnosed multiple myeloma; and the implications of this research on clinical practice.

Ciltacabtagene autoleucel demonstrated a significant improvement in progression-free survival in patients with relapsed/lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.

Maintenance therapy with carfilzomib, lenalidomide, and dexamethasone led to a significant improvement in progression-free survival vs lenalidomide alone in patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant after induction therapy, according to an unplanned interim analysis of the phase 3 ATLAS trial.

In this third episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, highlights the efficacy and safety profile of teclistamab, a BCMA-directed bispecific T-cell engager, in heavily pretreated multiple myeloma.

Sergio A. Giralt, MD, discusses long-term outcomes with hematopoietic stem cell transplant in multiple myeloma

Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.

David Siegel, MD, PhD, discusses the evaluation of idecabtagene vicleucel in cohort 2C of the KarMMa-2 trial and what these data could mean for this population and others with multiple myeloma.

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Ajay Chari, MD, discusses several avenues for future study in newly diagnosed multiple myeloma.

In this second episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, discusses the depth of response reported with daratumumab, carfilzomib, lenalidomide, and dexamethasone in transplant-eligible multiple myeloma.

The panel closes their discussion by highlighting unmet needs in the multiple myeloma treatment landscape and sharing advice for physicians and patients.

Krina Patel, MD, explains the treatment options for patients with early relapsed multiple myeloma.

The addition of daratumumab to lenalidomide and dexamethasone led to a 27% reduction in the risk of death compared with Rd alone in patients with relapsed/refractory multiple myeloma.

In this first episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, provides perspective on the use of daratumumab-based quadruplets as induction therapy in multiple myeloma.

Emma Searle, PhD, provides an overview of findings from the MajesTEC-2 trial in patients with relapsed/refractory multiple myeloma, elaborates on the safety of teclistamab plus daratumumab and lenalidomide, and discusses the next steps for evaluating the combination.

Dr Joseph Mikhael and expert panel re-visit the patient case and offer their final thoughts on the impact of clinical trial updates in the treatment landscape of multiple myeloma.

Ajai Chari, MD, shares some background on talquetamab, reported safety and efficacy findings from MonumenTAL-1, and highlighted other ways in which the agent is being explored in multiple myeloma.

Dr Joseph Mikhael and expert panel discuss key efficacy and safety outcomes of pivotal clinical trials evaluating treatment regimens in patients with R/R multiple myeloma.

Jenny Ahlstrom, a patient with multiple myeloma, shares considerations for patients going through treatment, including toxicities, follow-up, and travel planning.

Shaji Kumar, MD, and Krina Patel, MD, discuss the treatment options for patients with newly-diagnosed multiple myeloma who are not eligible for stem cell transplant.